Doma Perpetual Capital Management LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Doma Perpetual Capital Management LLC reported 11 stock positions worth $372.4 million. Its top holding was Pacira Biosciences (PCRX) at 16.9% of the portfolio, followed by Davita (DVA, 13.0%) and Merchants Bancorp (MBIN, 12.9%). Compared with Q4 2025, it opened 2 new positions, sold out of 3, added to 4 and reduced 1. The biggest buy was a new position in Intuit (INTU) and the biggest sale an exit from Pelagos Insurance Capital LT (PLGO).
- Most Recent 13F
- Q2 2026
- Location
- Miami, FL
- CIK
- 0001962221
- Portfolio Value
- $372.4M (Q1 2026)
- SEC Filing
- 0001172661-26-002097 ↗ filed May 15, 2026
Holdings Value
Holdings 11 stocks · $372.4M
| PCRX Pacira Biosciences Inc. | 16.86% | 2,777,794 | $62.8M | No change |
| DVA Davita Inc. | 13.04% | 316,025 | $48.6M | Add +4.3% |
| MBIN Merchants Bancorp | 12.85% | 1,115,594 | $47.9M | No change |
| INMD Inmode Ltd. | 11.27% | 3,067,431 | $42.0M | Add +8.1% |
| AFYA Afya Ltd. Class A | 9.12% | 2,285,093 | $34.0M | Add +9.7% |
| HIFS Hingham Institution for SVGS | 9.01% | 117,354 | $33.5M | No change |
| NOMD Nomad Foods Ltd. | 8.62% | 3,340,330 | $32.1M | Add +17.1% |
| NSSC Napco Security Technologies | 6.64% | 627,931 | $24.7M | No change |
| INTU Intuit Inc. | 5.11% | 44,000 | $19.0M | New |
| KNSL Kinsale Capital Group Inc. | 4.59% | 50,051 | $17.1M | Reduce -10.7% |
| ROP Roper Technologies Inc. | 2.88% | 30,330 | $10.7M | New |
Portfolio Sells Q4 2025 → Q1 2026
Portfolio Buys Q4 2025 → Q1 2026
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 13 | $430.8M | PCRX, NOMD, MBIN, INMD, HIFS |
| Q1 2026 | 11 | $372.4M | PCRX, DVA, MBIN, INMD, AFYA |
| Q4 2025 | 12 | $355.6M | PCRX, INMD, MBIN, NOMD, DVA |
| Q3 2025 | 12 | $297.8M | PCRX, NSSC, DVA, INMD, SIRI |
| Q2 2025 | 10 | $264.0M | BBD, PCRX, DVA, NSSC, INMD |
| Q1 2025 | 10 | $254.4M | PCRX, DVA, INMD, BBD, NSSC |
| Q4 2024 | 8 | $201.0M | INMD, PCRX, SIRI, BBD, NSSC |
| Q3 2024 | 8 | $198.0M | INMD, BBD, NSSC, SIRI, PCRX |
| Q2 2024Amended | 9 | $215.6M | DVA, INMD, PCRX, BBD, LSXMK |
| Q1 2024Amended | 9 | $150.3M | DVA, LSXMK, PCRX, INMD, NSSC |